US FDA approves Inovio's treatment for rare throat disease; shares surge

Oct 30 (Reuters) - The US Food and ‌Drug Administration has ‌approved Inovio Pharmaceuticals' treatment ​for a rare respiratory condition, the regulator said on ‌Friday, marking ⁠the company's first approved product.

Shares ⁠of Inovio were up 215% in ​extending trading.

Inovio's ​therapy ​INO-3107, branded ‌as Voceryq, gives patients with recurrent respiratory papillomatosis a new treatment option for ‌the condition, ​which causes ​growths ​in the ‌airways and often requires ​repeated ​surgeries.

(Reporting by Sahil Pandey, Christy Santhosh ​and ‌Siddhi Mahatole in ​Bengaluru; Editing by ​Shailesh Kuber)